Skip to main navigation

Contact Us
Careers

facebook
instagram
linkedin
twitter

Our Company
Our Science
Our Therapies
Rare Life
Investors & Media

EVENT DETAILS

Home ▶
Investors & Media ▶
Travere Therapeutics Corporate Update Call – FILSPARI® in IgA Nephropathy Phase 3 PROTECT Study Results

Travere Therapeutics Corporate Update Call – FILSPARI® in IgA Nephropathy Phase 3 PROTECT Study Results

Sep 21, 2023 at 8:30 AM EDT

Supporting Materials

Travere Therapeutics Corporate Update - PROTECT Study Results Presentation 1.4 MB

Download Library

↑ Return to Top

facebook
instagram
linkedin
twitter

Terms & Conditions
Privacy
Do Not Sell or Share My Personal Information

© 2024 Travere Therapeutics, Inc. All rights reserved. For US audiences. Total Care Hub® and Filspari® are registered trademarks of Travere Therapeutics, Inc. Travere TotalCare® is a trademark of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.